Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
filingDate |
2009-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2014-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7aede69d82056f0c165608576e1b5ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a0928dc5560b2e46e101001b6f91a70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_450d602ac5ed45ee09fc5b4b3d49cb5f |
publicationDate |
2014-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
RU-2532378-C2 |
titleOfInvention |
Combination of insulin and glp-1 agonist |
abstract |
FIELD: medicine. n SUBSTANCE: group of inventions concerns a kit for treating diabetes comprising the first pharmaceutical composition and the second pharmaceutical composition, wherein the first pharmaceutical composition contains Gly(A21)-Arg(B31)-Arg(B32) human insulin, and the second pharmaceutical composition contains Gly(A21)-Arg(B31)-Arg(B32) human insulin and desPro 36 exendin-4(1-39)-Lys 6 -NH 2 ; using the kit for preparing a medicated product for treating a patient suffering from diabetes for controlling the blood glucose concentration on an empty stomach, after meals and/or after absorption, or for improving the glucose tolerance. n EFFECT: group of inventions enables achieving the synergetic effect of the combination of the above compounds. n 13 cl, 14 ex, 10 dwg |
priorityDate |
2008-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |